Inhibition of Ca2+/calmodulin-dependent protein kinase or epidermal growth factor receptor tyrosine kinase abolishes lysophosphatidic acid-mediated DNA-synthesis in human myometrial smooth muscle cells

Cell Biology International

Volumn 27, Issue 4, 2003, Pages 341-347

  Nilsson, Ulrika K ^a   Svensson, Samuel P S ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Calcium; Calmodulin; DNA synthesis; Epidermal growth factor; Lysophosphatidic acid; Smooth muscle cells

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; RECEPTOR SUBTYPE; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; DNA; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LYSOPHOSPHOLIPID;

ARTICLE; BIOPSY; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CESAREAN SECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE FIBER CULTURE; MYOMETRIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; BIOSYNTHESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MYOCYTES, SMOOTH MUSCLE; MYOMETRIUM; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0037764061     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1065-6995(02)00352-9     Document Type: Article

References (44)

1. Adolfsson P.I., Ahlstrand C., Varenhorst E., Svensson S.P.S. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: Sildenafil and Papaverin generate inhibition. Prostate. 51:2002;50-58.
2. An S., Dickens M.A., Bleu T., Hallmark O.G., Goetzl E.J. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem Biophys Res Commun. 231:1997;619-622.
3. An S., Bleu T., Hallmark O.G., Goetzl E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem. 273:1998;7906-7910.
4. Bacon R.L., Niles N.R. Medical histology: a text-atlas with introductory pathology. 1983;Springer, New York. p. 368-73.
5. Bandoh K., Aoki J., Hosono H., Kobayashi S., Kobayashi T., Murakami-Murofushi K., et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 274:1999;27776-27785.
6. Bornfeldt K.E., Gidlöf R.A., Wasteson Å., Lake M., Skottner A., Arnqvist H.J. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia. 34:1991;307-313.
7. Buist A., Tertoolen L.G.J., den Hertog J. Potentiation of G-protein-coupled receptor-induced MAP kinase activation by exogenous EGF receptors in SK-N-MC neuroepithelioma cells. Biochem Biophys Res Commun. 251:1998;6-10.
8. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol Rev. 59:1979;1-61.
9. 125I-epidermal growth factor in human uterus. Cell Tissue Res. 246:1986;543-548.
10. 2+-dependent signal pathways in Rat-1 cells. J Biol Chem. 272:1997;13309-13319.
11. Daub H., Weiss F.U., Wallasch C., Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 379:1996;557-560.
12. Della Rocca G.J., Maudsley S., Daaka Y., Lefkowitz R.J., Luttrell L.M. Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. J Biol Chem. 274:1999;13978-13984.
13. Dong J., Opresko L.K., Dempsey P.J., Lauffenburger D.A., Coffey R.J., Wiley H.S. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A. 96:1999;6235-6240.
14. Eguchi S., Numaguchi K., Iwasaki H., Matsumoto T., Yamakawa T., Utsunomiya H., et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 273:1998;8890-8896.
15. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 291:1993;677-680.
16. 2generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 80:1995;919-927.
17. Goetzl E.J., An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 12:1998;1589-1598.
18. Gogarten W., Emala C.W., Lindeman K.S., Hirshman C.A. Oxytocin and lysophosphatidic acid induce stress fiber formation in human myometrial cells via a pathway involving Rho-kinase. Biol Reprod. 65:2001;401-406.
19. Hecht J.H., Weiner J.A., Post S.R., Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol. 135:1996;1071-1083.
20. Hooks S.B., Santos W.L., Im D.-S., Heise C.E., MacDonald T.L., Lynch K.R. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem. 276:2001;4611-4621.
21. 2+stimulates the activation of mitogen-activated protein kinase and cell growth in human fibroblasts. Biochem J. 310:1995;881-885.
22. Im D.-S., Heise C.E., Harding M.A., George S.R., O'dowd B.F., Theodorescu D., et al. Molecular cloning and characterization of a lysophoshatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol. 57:2000;753-759.
23. Llewellyn-Jones D. Fundamentals of obstetrics and gynaecology. 6th ed. 1994;Mosby, London. p. 29-34.
24. 2+/calmodulin dependent protein kinase II inhibitor on cell cycle. Biochem Biophys Res Commun. 199:1994;241-248.
25. Motohashi K., Shibata S., Ozaki Y., Yatomi Y., Igarashi Y. Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett. 468:2000;189-193.
26. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res. 82:1998;1338-1348.
27. Murphy L.J., Murphy L.C., Friesen H.G. Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol Endocrinol. 1:1987;445-450.
28. i/o-protein-coupled receptors in human myometrial smooth muscle cells: a possible role of calcium. J Mol Neurosci. 11:1998;11-21.
29. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 402:1999;884-888.
30. Pulkkinen M., Hämäläinen M.M. Myometrial estrogen and progesterone receptor binding in pregnancy: inhibition by the detergent action of phospholipids. J Steroid Biochem Mol Biol. 52:1995;287-294.
31. Santella L. The role of calcium in the cell cycle: facts and hypotheses. Biochem Biophys Res Commun. 244:1998;317-324.
32. Seewald S., Sachinidis A., Düsing R., Ko Y., Seul C., Epping P., et al. Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells. Atherosclerosis. 130:1997;121-131.
33. Skalli O., Ropraz P., Trzeciak A., Benzonana G., Gillessen D., Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 103:1986;2787-2796.
34. Stancel G.M., Gardner R.M., Kirkland J.L., Lin T.H., Lingham R.B., Loose-Mitchell D.S., et al. Interactions between estrogen and EGF in uterine growth and function. Adv Exp Med Biol. 230:1987;99-118.
35. Tigyi G. Selective ligands for lysophosphatidic acid receptor subtypes: gaining control over endothelial differentiation gene family. Mol Pharmacol. 60:2001;1161-1164.
36. Tigyi G., Fischer D.J., Sebök Á., Marshall F., Dyer D.L., Miledi R. Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling. J Neurochem. 66:1996;549-558.
37. Tokumura A., Fukuzawa K., Isobe J., Tsukatani H. Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. Biochem Biophys Res Commun. 99:1981;391-398.
38. Tokumura A., Iimori M., Nishioka Y., Kitahara M., Sakashita M., Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol. 267:1994;C204-C210.
39. van Corven E.J., Groenink A., Jalink K., Eichholtz T., Moolenaar W.H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell. 59:1989;45-54.
40. Vogt W. Pharmacologically active acidic phospholipids and glycolipids. Biochem Pharmacol. 12:1963;415-420.
41. 2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine) in small cell lung carcinoma. Biochem Pharmacol. 51:1996;707-715.
42. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
43. Xu Y., Fang X.-J., Casey G., Mills G.B. Lysophospholipids activate ovarian and breast cancer cells. Biochem J. 309:1995;933-940.
44. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 280:1998;719-723.